Free Trial
NASDAQ:IKNA

Ikena Oncology Q1 2025 Earnings Report

Ikena Oncology logo
$1.37 +0.01 (+0.74%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.36 -0.02 (-1.09%)
As of 04:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ikena Oncology EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Ikena Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ikena Oncology Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Ikena Oncology's Q2 2025 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

Ikena Oncology Earnings Headlines

What a “Mar-a-Lago Accord” could mean for the US dollar.
25-Year Market Vet Issues Urgent Dollar Warning He's spent 25 years tracking the flow of global money - now he's coming forward with an urgent warning about a D.C. plan to deliberately crash the dollar. If it succeeds, you could see 40% of your savings vanish overnight. This free video explains why and gives you four important steps to take immediately.
William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)
See More Ikena Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email.

About Ikena Oncology

Ikena Oncology (NASDAQ:IKNA) operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

View Ikena Oncology Profile

More Earnings Resources from MarketBeat